Effect of 1-[4-[2-(4-bromobenzenesulfonamino)ethyl]phenylsulfonyl]-3- (trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 11, 2009, Pages 550-556

  Wu, Guan Zhong ^a   Hong, Gang ^b   Zhang, Wen Ping ^c   Zhang, Hui Bing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Province Certification Committee for Drugs ^*  (China)

^c ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

1 4 2 (4 Bromobenzenesulfonamino)ethyl phenylsulfonyl 3 (trans 4 methylcyclohexyl)urea; CAS 865483 06 3; Glucokinase; I4, hypoglycemic effect; Pancreatic islets

Indexed keywords

1 [4 [2 (4 BROMOBENZENESULFONAMINO)ETHYL]PHENYLSULFONYL] 3 (TRANS 4 METHYLCYCLOHEXYL)UREA; CAS 865483 06 3; GLIMEPIRIDE; GLUCOKINASE; INSULIN; STREPTOZOCIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HYPOGLYCEMIA; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID DIET; LIVER CELL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; RAT; STREPTOZOCIN DIABETES;

EID: 72449122800     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296443     Document Type: Article

References (35)

1. Grimaldi A, Heurtier A. Epidemiology of cardiovascular complications of diabetes. Diabetes Metab. 1999 Jun;25 Suppl 3:12-20.
2. Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD. ABC of arterial and venous disease. Vascular complications of diabetes. BMJ. 2000 Apr 15;320(7241):1062-1066 (Pubitemid 30198980)
3. Haffner SM, Lehto S, Ronnemaa T, Pyroala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23; 339(4):229-234 (Pubitemid 28350165)
4. Winocour PD. Platelets, vascular disease, and diabetes mellitus. Can J Physiol Pharmacol. 1994 Mar;72(3):295-303. (Pubitemid 24181932)
5. Sobol AB, Watala C. The role of platelets in diabetes related vascular complications. Diabetes Res Clin Pract. 2000 Sep;50(1):1-16.
6. Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The plavix use for treatment of diabetes (PLUTO-Diabetes) trial. Am Heart J. 2008 Jan;155(1):93.e1-7
7. Vinik AI, Vinik E. Prevention of the complications of diabetes. Am J Manag Care. 2003 Mar;9(3 Suppl):S63-80.
8. Scognamiglio R, Avogaro A, De Kreutzenberg SV, Negut C, Palisi M, Bagolin E, et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes. 2002 Mar;51(3): 808-812
9. Zingg W, Leibel BS. Modification of platelet adhesion by antiplatelet drugs helps prevent cardiovascular complications of diabetes mellitus. Med Hypotheses. 1985 Oct;18(2): 119-127
10. Melero PS, De Antolinez AN. Oral anti-diabetes medicines, an update. Rev. Enferm. 2008 Mar;31(3):7-10.
11. Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007 Sep;23(6):479-484
12. Green JB, Feinglos MN. Are sulfonylureas passé? Curr Diab Rep. 2006 Nov;6(5):373-377
13. Guerra SD, Grupillo M, Masini M, Lupi R, Bugliani M, Torri S, et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev. 2007 Mar;23(3):234-238
14. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-512
15. Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Ann Pharmacother. 2003 Nov;37(11):1572-1576
16. Krauss H, Kozlik J, Grzymislawski M, Sosnowski P, Mikrut K, Piatek J. The influence of glimepiride on the oxidative state of rats with streptozotocin-induced hyperglycemia. Med Sci Monit. 2003 Nov;9(11):BR389-93.
17. Zhang HB, Zhang YA, Wu GZ, Zhou JP, Huang WL, Hu XW. Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents. Bioorg Med Chem Lett. 2009;19(6):1740-1744
18. Zhang WP, Wu GZ, Liu GQ. Effects and mechanisms of compound G004 on experimental thrombosis. China Clin Pharmacol Ther. 2005;10:162-167
19. Ye Fei. Pharmacological Experiment Methods and Technology in Diabetes Mellitus. In: Zhang JT (editor). Modern Pharmacological Experiment Methods. Beijing: Peking medical university and Chinese academy of medicine science press. 1998. p. 984-987.
20. Wu GZ, Forman BL. Study on effect and its mechanism of deoxyadenosine on insulin secretion of rat isolated islets of langerhans. J China Pharm Univ. 1996;27:421-424
21. Grodsky GM, Fanska RE. The in vitro perfused pancreas. Methods Enzymol. 1975;39:364-372
22. James KM, Charles EO, Douglas EE. Thermostable continuous coupled assay for measuring glucose using glucokinase and glucose-6-phosphate dehydrogenase from the marine hyperthermophile Thermotoga maritime. Anal Biochem. 2003 Jul 15;318(2):196-203.
23. Ye Fei. Determination of Glycogen Synthesis and Gluconeogenesis. In: Zhang JT (editor). Modern Pharmacological Experiment Methods. Beijing: Peking medical university and Chinese academy of medicine science press. 1998. p. 1006-1007.
24. Guerra SD, Parentini C, Bracci C, Lupi R, Marselli L, Aragona M, et al. Insulin release from isolated human islets after acute or prolonged exposure to glimepiride. Acta Diabetol. 2000;37(3):139-141 (Pubitemid 32157315)
25. Lupi R, Marchetti P, Giannarelli R, Coppelli A, Tellini C, Guerra SD, et al. Effects of glibenclamide and metformin (alone or in combination) on insulin release from isolated humanpancreatic islets. Acta Diabetol. 1997 Mar;34(1):46-48
26. Nesher R, Cerasi E. Modeling Phasic Insulin Release: Immediate and Time-Dependent Effects of Glucose. Diabetes. 2002 Feb;51 Suppl 1:S53-9.
27. Prato SD, Marchetti P, Riccardo CB. Phasic Insulin Release and Metabolic Regulation in Type 2 Diabetes. Diabetes. 2002 Feb;51 Suppl 1:S109-S116.
28. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol. 1989 Aug;257(2 Pt 1): E241-6.
29. Feldman JM, Lebovitz HE. Appraisal of the extrapancreatic actions of sulfonylureas. Arch Intern Med. 1969 Mar;123(3): 314-322
30. Beck-Nielsen H, Hother NO, Pedersen O. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet. Med. 1988 Oct;5(7):613-620 (Pubitemid 18239420)
31. Garvey WT. Glucose transport and NIDDMDiabetes Care. 1992 Mar;15(3):396-417.
32. Muller G, Wied S, Wetekam EM, Crecelius A, Unkelbach A, Punter J, et al. Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulphonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade. Biochem Pharmacol. 1994 Aug 30;48(5):985-996
33. Wu GZ, Hong G, Wang GJ. Hypoglycemic effect and its mechanism of novel compound G-003. Chin Pharmacol Bull. 2004;20:1026-1030
34. Kunte H, Schmidt S, Eliasziw M, Zoppo GJD, Simard JM, Masuhr F, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007 Sep;38(9):2526-2530
35. Del GS, Grupillo M, Masini M, Lupi R, Bugliani M, Torri S, et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev. 2007 Mar;23(3):234-238